WO2010067286A3 - IgE CH3 PEPTIDE VACCINE - Google Patents

IgE CH3 PEPTIDE VACCINE Download PDF

Info

Publication number
WO2010067286A3
WO2010067286A3 PCT/IB2009/055508 IB2009055508W WO2010067286A3 WO 2010067286 A3 WO2010067286 A3 WO 2010067286A3 IB 2009055508 W IB2009055508 W IB 2009055508W WO 2010067286 A3 WO2010067286 A3 WO 2010067286A3
Authority
WO
WIPO (PCT)
Prior art keywords
ige
peptide vaccine
relates
immunogens
alleviation
Prior art date
Application number
PCT/IB2009/055508
Other languages
French (fr)
Other versions
WO2010067286A2 (en
Inventor
Alan Daniel Brown
Brian Robert Champion
Clare Christy
David Paul Gervais
Lyn Howard Jones
Anne Maria Kristina Kjerrstrom
David Cameron Pryde
Lee Richard Roberts
David Michael Wyatt
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42035836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010067286(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BRPI0922561-7A priority Critical patent/BRPI0922561A2/en
Priority to KR1020137003578A priority patent/KR101644221B1/en
Priority to KR1020157012347A priority patent/KR101634058B1/en
Priority to NZ592977A priority patent/NZ592977A/en
Priority to EP09793590.2A priority patent/EP2376108B1/en
Priority to CA2744754A priority patent/CA2744754A1/en
Priority to CN200980149635.5A priority patent/CN102245198B/en
Priority to DK09793590.2T priority patent/DK2376108T3/en
Priority to MX2013006964A priority patent/MX337723B/en
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Priority to KR1020117015895A priority patent/KR101413844B1/en
Priority to MX2011006077A priority patent/MX2011006077A/en
Priority to JP2011540292A priority patent/JP5209800B2/en
Priority to RU2011121043/10A priority patent/RU2495049C2/en
Priority to ES09793590.2T priority patent/ES2622562T3/en
Priority to AU2009325950A priority patent/AU2009325950B2/en
Publication of WO2010067286A2 publication Critical patent/WO2010067286A2/en
Publication of WO2010067286A3 publication Critical patent/WO2010067286A3/en
Priority to IL213029A priority patent/IL213029A0/en
Priority to ZA2011/04072A priority patent/ZA201104072B/en
Priority to HK12104022.0A priority patent/HK1163511A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Abstract

The present invention relates to the provision of immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
PCT/IB2009/055508 2008-12-09 2009-12-04 IgE CH3 PEPTIDE VACCINE WO2010067286A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
AU2009325950A AU2009325950B2 (en) 2008-12-09 2009-12-04 IgE CH3 peptide vaccine
MX2011006077A MX2011006077A (en) 2008-12-09 2009-12-04 IgE CH3 PEPTIDE VACCINE.
KR1020117015895A KR101413844B1 (en) 2008-12-09 2009-12-04 IgE CH3 PEPTIDE VACCINE
JP2011540292A JP5209800B2 (en) 2008-12-09 2009-12-04 IgECH3 peptide vaccine
KR1020137003578A KR101644221B1 (en) 2008-12-09 2009-12-04 IgE CH3 PEPTIDE VACCINE
CA2744754A CA2744754A1 (en) 2008-12-09 2009-12-04 Ige ch3 peptide vaccine
CN200980149635.5A CN102245198B (en) 2008-12-09 2009-12-04 IgE CH3 peptide vaccine
DK09793590.2T DK2376108T3 (en) 2008-12-09 2009-12-04 IgE CH3 peptide vaccine
MX2013006964A MX337723B (en) 2008-12-09 2009-12-04 IgE CH3 PEPTIDE VACCINE.
BRPI0922561-7A BRPI0922561A2 (en) 2008-12-09 2009-12-04 ige ch3 peptide vaccine.
KR1020157012347A KR101634058B1 (en) 2008-12-09 2009-12-04 IgE CH3 PEPTIDE VACCINE
EP09793590.2A EP2376108B1 (en) 2008-12-09 2009-12-04 IgE CH3 PEPTIDE VACCINE
NZ592977A NZ592977A (en) 2008-12-09 2009-12-04 IgE CH3 PEPTIDE VACCINE
RU2011121043/10A RU2495049C2 (en) 2008-12-09 2009-12-04 Ch3 ige peptide vaccine
ES09793590.2T ES2622562T3 (en) 2008-12-09 2009-12-04 IgE CH3 peptide vaccine
IL213029A IL213029A0 (en) 2008-12-09 2011-05-19 IgE CH3 PEPTIDE VACCINE
ZA2011/04072A ZA201104072B (en) 2008-12-09 2011-06-01 Ige ch3 peptide vaccine
HK12104022.0A HK1163511A1 (en) 2008-12-09 2012-04-24 Ige ch3 peptide vaccine ige ch3

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12098908P 2008-12-09 2008-12-09
US61/120,989 2008-12-09

Publications (2)

Publication Number Publication Date
WO2010067286A2 WO2010067286A2 (en) 2010-06-17
WO2010067286A3 true WO2010067286A3 (en) 2010-08-05

Family

ID=42035836

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/055508 WO2010067286A2 (en) 2008-12-09 2009-12-04 IgE CH3 PEPTIDE VACCINE

Country Status (22)

Country Link
US (3) US8298547B2 (en)
EP (2) EP2376108B1 (en)
JP (4) JP5209800B2 (en)
KR (3) KR101413844B1 (en)
CN (1) CN102245198B (en)
AR (1) AR074505A1 (en)
AU (1) AU2009325950B2 (en)
BR (1) BRPI0922561A2 (en)
CA (1) CA2744754A1 (en)
CO (1) CO6561830A2 (en)
DK (1) DK2376108T3 (en)
ES (1) ES2622562T3 (en)
HK (1) HK1163511A1 (en)
IL (1) IL213029A0 (en)
MX (2) MX337723B (en)
NZ (2) NZ592977A (en)
PE (2) PE20110891A1 (en)
RU (1) RU2495049C2 (en)
SG (2) SG186611A1 (en)
TW (1) TWI387463B (en)
WO (1) WO2010067286A2 (en)
ZA (1) ZA201104072B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105017423B (en) * 2005-08-11 2019-06-04 阿皮·马托西安-罗杰斯 TCR-V- beta related peptides for treatment of autoimmune diseases and diagnosis
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
EP2376107B1 (en) 2008-12-09 2014-05-21 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
US9315814B2 (en) 2011-05-26 2016-04-19 Intervet Inc. Immunostimulatory oligodeoxynucleotides
EP2714907B1 (en) * 2011-05-26 2016-06-15 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
US9956276B2 (en) 2012-01-19 2018-05-01 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
US9657071B2 (en) 2012-06-18 2017-05-23 Nippon Zenyaku Kogyo Co., Ltd. IgE peptide vaccine
WO2016007504A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
WO2016007499A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
CN107074925B (en) 2014-07-10 2021-08-24 阿费里斯股份公司 Materials and methods for preventing and/or treating huntington's disease
CN108472358B (en) * 2015-09-30 2022-06-24 盐野义制药株式会社 Nucleic acid derivatives with immunopotentiating activity
KR101876620B1 (en) * 2015-10-27 2018-07-09 대구한의대학교산학협력단 The norovirus detection chip using peptide binders via peptidomimetics for human and the manufacturing method
CN108697779B (en) 2016-01-07 2023-09-19 杜克大学 Cancer vaccine and delivery method
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
MY186779A (en) * 2017-03-29 2021-08-19 Shionogi & Co Nucleic acid derivative having immunostimulatory activity
CA3192500A1 (en) 2020-09-17 2022-03-24 Laurent REBER Immunogenic product comprising an ige fragment for treating ige-mediated inflammatory disorders
WO2023192203A2 (en) * 2022-03-28 2023-10-05 The Regents Of The University Of California Novel plant virus and bacteriophage vaccines

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263655A2 (en) * 1986-10-03 1988-04-13 Dainippon Pharmaceutical Co., Ltd. Novel peptides having antiallergic activity
WO1999067293A1 (en) * 1998-06-20 1999-12-29 United Biomedical Inc. Peptide composition as immunogen for the treatment of allergy
EP1195161A2 (en) * 2000-08-30 2002-04-10 Pfizer Products Inc. Anti-IgE vaccines
WO2004058799A2 (en) * 2002-12-20 2004-07-15 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of ige to a high affinity receptor
WO2004084940A1 (en) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980000727A1 (en) 1978-09-29 1980-04-17 Secretary Energy Brit Improvements in and relating to electrical power transmission in fluid wells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
JP2547714B2 (en) 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド Oligonucleotide therapeutic agent and method for producing the same
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
US5258289A (en) * 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
SE9102808L (en) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo VACCIN, HOW TO USE HUMAN USE, WILL BE INTENDED TO EFFECT THE SYMPTOMS OR PREVENT THE RISE OF IGE-MEDIATED ALLERGIC REACTIONS
UA40597C2 (en) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition, method for treatment of mammals, diseased or receptive to the infection, method for treatment of mammals with cancer, method for production of vaccine composition, composition of adjuvants
ATE204762T1 (en) 1993-03-23 2001-09-15 Smithkline Beecham Biolog VACCINE COMPOSITIONS CONTAINING 3-0-DEAZYLATED MONOPHOSPHORYL LIPID A
DE4321946A1 (en) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonic acid esters, process for their preparation and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
CN1185811A (en) 1995-03-31 1998-06-24 H·沃尔夫 Antigen presentation system on retrovirus-like particles
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
CA2245497C (en) 1996-03-01 2009-02-24 Novartis Ag Peptide immunogens for vaccination against and treatment of allergy
ID18046A (en) 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd COMPOUND, MIXED CYCLE, MANUFACTURE AND USE OF IT.
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2241042T3 (en) 1996-10-11 2005-10-16 The Regents Of The University Of California IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA.
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DE69841122D1 (en) 1997-03-10 2009-10-15 Coley Pharm Gmbh Use of non-methylated CpG dinucleotide in combination with aluminum as adjuvants
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
EP2085090A3 (en) 1997-06-06 2012-05-02 The Regents of the University of California Inhibitors of DNA immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
DE69911175T2 (en) 1998-02-12 2004-07-29 Apovia, Inc., San Diego STRATEGICALLY MODIFIED HEPATITIS B CORE PROTEINS AND THEIR DERIVATIVES
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
US6734287B1 (en) * 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
ES2234180T3 (en) * 1998-04-09 2005-06-16 Idexx Laboratories, Inc. SPECIFIC FIXING PROTEINS FOR THE TREATMENT OF CANINE ALLERGY.
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ES2233101T3 (en) 1998-09-03 2005-06-01 Chiron Corp UNIT DOSE OF ANGIOGENICALLY EFFECTIVE FGF-2 AND ITS USE.
WO2000017158A1 (en) 1998-09-18 2000-03-30 Pentapharm Ag Urokinase inhibitors
KR100629028B1 (en) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. Adjuvant systems and vaccines
EP1123114B1 (en) 1998-10-21 2005-12-28 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Virus-like particles for the induction of autoantibodies
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
DE69929470T2 (en) 1998-11-05 2006-08-24 Powderject Vaccines, Inc., Madison GENE CONSTRUCTS FOR GENIMMUNIZATION
CA2354183A1 (en) 1998-11-30 2000-06-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
US20030170229A1 (en) * 1999-02-25 2003-09-11 Smithkline Beecham Biologicals S.A. Vaccine
PL350992A1 (en) * 1999-02-25 2003-02-24 Smithkline Beecham Biolog Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
AR022963A1 (en) 1999-03-19 2002-09-04 Smithkline Beecham Biolog VACCINE
WO2000058365A1 (en) * 1999-03-30 2000-10-05 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
CA2383413A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
KR20020048942A (en) 1999-09-24 2002-06-24 장 스테판느 Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one nonionic surfactant
JP2003510290A (en) 1999-09-27 2003-03-18 コーリー ファーマシューティカル グループ，インコーポレイテッド Methods for immunostimulatory nucleic acid-induced interferons
PT1268530E (en) 2000-04-07 2006-12-29 Univ Leeds Hepatitis b core antigen fusion proteins
EP1278542A2 (en) 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
JP2004500868A (en) 2000-06-22 2004-01-15 セルテック　ファーマスーティカルズ　リミテッド Modification of hepatitis B core antigen
AU2001269272A1 (en) 2000-07-15 2002-01-30 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
GB0026334D0 (en) 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
EP1450856B1 (en) * 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP1517702A4 (en) 2002-02-21 2006-05-03 Apovia Inc IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
US20040176283A1 (en) 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CU22983A1 (en) * 2002-05-08 2004-09-09 Inst Finlay VACCINE COMPOSITION AGAINST ALLERGIES AND METHOD FOR OBTAINING AND EMPLOYMENT IN THE TREATMENT OF THE SAME
ATE542828T1 (en) 2002-07-17 2012-02-15 Cytos Biotechnology Ag MOLECULAR ANTIGEN ARRANGEMENT USING A VIRUS-LIKE PARTICLE FROM VIRUS AP205
CN1838967B (en) 2002-12-10 2010-05-26 洛伦蒂斯有限公司 Stabilized immunogenic HBc chimer particles
KR101562114B1 (en) 2004-02-02 2015-11-20 타녹스 인코퍼레이티드 IDENTIFICATION OF NOVEL IgE EPITOPES
JP2008506683A (en) 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド Methods and compositions for inducing innate immune responses
KR100958505B1 (en) 2004-07-18 2010-05-17 씨에스엘 리미티드 Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
WO2007028985A2 (en) * 2005-09-07 2007-03-15 The Secretary Of State For Defence Adjuvanted vaccine
ES2553284T5 (en) 2006-02-15 2021-08-31 Rechtsanwalt Thomas Beck Compositions and Procedures for Oligonucleotide Formulations
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
UY30994A1 (en) 2007-04-02 2008-11-28 Amgen Fremont Inc ANTI-IGE ANTIBODIES
DK2158211T3 (en) * 2007-05-31 2016-12-05 Medigene Ag Mutated structural protein of a parvovirus
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users
JP6911110B2 (en) 2016-06-23 2021-07-28 リップルズ エルティーディー．Ｒｉｐｐｌｅｓ Ｌｔｄ． Methods and equipment for printing on beverages

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263655A2 (en) * 1986-10-03 1988-04-13 Dainippon Pharmaceutical Co., Ltd. Novel peptides having antiallergic activity
WO1999067293A1 (en) * 1998-06-20 1999-12-29 United Biomedical Inc. Peptide composition as immunogen for the treatment of allergy
EP1195161A2 (en) * 2000-08-30 2002-04-10 Pfizer Products Inc. Anti-IgE vaccines
US20060062782A1 (en) * 2000-08-30 2006-03-23 Morsey Mohamad A Anti-IgE vaccines
WO2004058799A2 (en) * 2002-12-20 2004-07-15 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of ige to a high affinity receptor
WO2004084940A1 (en) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use

Also Published As

Publication number Publication date
US9216229B2 (en) 2015-12-22
IL213029A0 (en) 2011-07-31
JP5209800B2 (en) 2013-06-12
JP5367137B2 (en) 2013-12-11
US8475801B2 (en) 2013-07-02
CA2744754A1 (en) 2010-06-17
RU2011121043A (en) 2013-01-20
KR20130032390A (en) 2013-04-01
SG186611A1 (en) 2013-01-30
CO6561830A2 (en) 2012-11-15
JP2012255006A (en) 2012-12-27
EP2376108B1 (en) 2017-02-22
JP5964280B2 (en) 2016-08-03
KR20150056881A (en) 2015-05-27
BRPI0922561A2 (en) 2020-08-11
US20120294848A1 (en) 2012-11-22
EP2376108A2 (en) 2011-10-19
PE20142330A1 (en) 2015-01-14
MX337723B (en) 2016-03-15
NZ604186A (en) 2014-07-25
US20140017239A1 (en) 2014-01-16
JP2016164156A (en) 2016-09-08
TW201036632A (en) 2010-10-16
WO2010067286A2 (en) 2010-06-17
DK2376108T3 (en) 2017-04-24
AU2009325950B2 (en) 2013-03-07
US20100158933A1 (en) 2010-06-24
RU2495049C2 (en) 2013-10-10
EP2865389A1 (en) 2015-04-29
AR074505A1 (en) 2011-01-19
HK1163511A1 (en) 2012-09-14
JP2012511322A (en) 2012-05-24
TWI387463B (en) 2013-03-01
CN102245198A (en) 2011-11-16
KR20110094134A (en) 2011-08-19
NZ592977A (en) 2013-01-25
KR101634058B1 (en) 2016-06-27
ZA201104072B (en) 2012-02-29
CN102245198B (en) 2016-08-17
AU2009325950A1 (en) 2010-06-17
ES2622562T3 (en) 2017-07-06
US8298547B2 (en) 2012-10-30
PE20110891A1 (en) 2011-12-23
SG10201400388QA (en) 2014-05-29
KR101413844B1 (en) 2014-06-30
KR101644221B1 (en) 2016-07-29
MX2011006077A (en) 2011-09-01
JP2014012009A (en) 2014-01-23

Similar Documents

Publication Publication Date Title
WO2010067286A3 (en) IgE CH3 PEPTIDE VACCINE
WO2011027257A3 (en) Pcsk9 vaccine
EP2942061A3 (en) Ige ch3 peptide vaccine
WO2006099169A3 (en) Novel liposome compositions
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
MX2012001194A (en) Antigenic tau peptides and uses thereof.
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
WO2007054283A3 (en) Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions
EA200701519A1 (en) LIVE ATTENUATED ROTAVIRAL VACCINE FOR ORAL ADMINISTRATION
WO2011035335A3 (en) Stabilized liquid and lyophilized adamts13 formulations
WO2009135190A3 (en) Therapeutic calcium phosphate particles and methods of making and using same
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
WO2011143201A3 (en) Ratiometric combinatorial drug delivery
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
PH12015500062A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
WO2007059931A8 (en) New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions
WO2010089443A3 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING TGF- β1 INHIBITOR PEPTIDES
WO2011060253A3 (en) Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms
WO2008028667A3 (en) Use of glycolipids as adjuvants
WO2011006084A3 (en) Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof
WO2008024753A3 (en) Lipid-derived nanoparticles for brain-targeted drug delivery
WO2014055941A8 (en) Compounds and methods for targeted immune system delivery
BR112015023872A2 (en) composition comprising arabinogalactan and polyphenols of larch trees

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980149635.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09793590

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009325950

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3625/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 213029

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 592977

Country of ref document: NZ

REEP Request for entry into the european phase

Ref document number: 2009793590

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2744754

Country of ref document: CA

Ref document number: 2009793590

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009325950

Country of ref document: AU

Date of ref document: 20091204

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 001186-2011

Country of ref document: PE

Ref document number: 12011501142

Country of ref document: PH

Ref document number: MX/A/2011/006077

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011540292

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11072267

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20117015895

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011121043

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 000753-2014

Country of ref document: PE

ENP Entry into the national phase

Ref document number: PI0922561

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110608